TABLE 3.
Laboratory and clinical data from 1 and 6 mo posttransplant
| Women ≤50 y (N = 12) | Women >50 y (N = 10) |
Men ≤50 y (N = 18) | Men >50 y (N = 26) |
|
|---|---|---|---|---|
| 1-mo laboratory measurements, mean (SD) | ||||
| WBC | 8.46 (3.62) | 9.08 (3.89) | 6.95 (2.71) | 8.03 (2.69) |
| ANC, K/µL | 6.74 (2.95) | 7.59 (3.58) | 5.34 (2.15) | 6.44 (2.13) |
| ALC, K/µL | 0.99 (0.91) | 0.79 (0.53) | 0.86 (0.73) | 0.81 (0.62) |
| CD4+, K/µL | 0.38 (0.51) | 0.34 (0.29) | 0.39 (0.46) | 0.35 (0.31) |
| CD8+, K/µL | 0.23 (0.25) | 0.23 (0.26) | 0.19 (0.18) | 0.18 (0.17) |
| CD3+, KµL | 0.62 (0.78) | 0.57 (0.49) | 0.59 (0.61) | 0.54 (0.45) |
| CD4+/CD8+ ratio | 1.12 (0.89) | 2.10 (2.24) | 1.78 (1.83) | 2.65 (2.34) |
| Total IgG, mg/dL | 679.4 (225.5) | 576.3 (319.1) | 770.2 (325.2) | 597.8 (224.9) |
| eGFRa | 60.08 (36.86) | 63.30 (20.96) | 64.94 (35.14) | 58.27 (31.51) |
| Tacrolimus level | 9.55 (2.20) | 7.87 (2.45) | 7.82 (2.84) | 7.85 (3.11) |
| Valganciclovir/ganciclovir at time of 1-mo laboratory values, n (%) | 4 (33.3) | 6 (60.0) | 7 (41.2) | 13 (50.0) |
| Reduction or discontinuation of mycophenolate at time of 1 mo laboratory values, n (%) | 1 (8.3) | 0 (0) | 1 (5.5) | 4 (15) |
| TMP-SMX at time of 1-mo laboratory values, n (%) | 12 (100.0) | 9 (90.0) | 17 (100.0) | 24 (92.3) |
| 6-mo laboratory measurements, mean (SD) | ||||
| WBC | 5.79 (2.53) | 4.68 (1.81) | 5.88 (2.75) | 5.70 (2.38) |
| ANC, K/µL | 4.03 (2.13) | 3.44 (1.48) | 4.18 (2.17) | 4.04 (1.85) |
| ALC, K/µL | 0.90 (0.55) | 0.59 (0.34) | 0.82 (0.41) | 0.85 (0.52) |
| CD4+, K/µL | 0.31 (0.32) | 0.22 (0.15) | 0.30 (0.20) | 0.34 (0.23) |
| CD8+, K/µL | 0.23 (0.15) | 0.23 (0.18) | 0.19 (0.11) | 0.22 (0.18) |
| CD3+, K/µL | 0.56 (0.47) | 0.44 (0.26) | 0.51 (0.29) | 0.57 (0.32) |
| CD4+/CD8+ ratio | 1.08 (0.70) | 1.39 (1.12) | 1.65 (1.27) | 2.47 (2.66) |
| Total IgG, mg/dL | 655.2 (207.0) | 663.0 (292.2) | 839.9 (293.5) | 585.0 (171.8) |
| eGFRa | 59.17 (26.90) | 41.00 (17.36) | 61.88 (19.71) | 48.19 (20.82) |
| Tacrolimus level | 7.65 (3.31) | 7.19 (1.46) | 6.81 (2.83) | 8.10 (2.19) |
| Valganciclovir/ganciclovir at time of 6-mo laboratory values, n (%) | 3 (25.0) | 1 (10.0) | 2 (12.5) | 3 (11.5) |
| TMP-SMX at time of 6-mo laboratory values, n (%) | 11 (91.7) | 9 (90.0) | 14 (87.5) | 18 (69.2) |
| Reduction or discontinuation of mycophenolate at time of 6-mo laboratory values, n (%) | 5 (42) | 8 (80) | 4 (25) | 18 (69) |
| Belatacept use at time of 6-mo laboratory values, n (%) | 3 (25.0) | 0 (0.0) | 7 (43.8) | 1 (4.0) |
| Treatment for rejection in first 6 mo, n (%) | 4 (33.3) | 5 (50.0) | 3 (16.7) | 6 (23.1) |
| Treatment included ATG | 1 (8.3) | 0 (0.0) | 2 (11.1) | 1 (3.8) |
| Treatment included rituximab | 1 (8.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
aCalculated according to the CKD-EPI equation based on serum creatinine.
ALC, absolute lymphocyte count; ANC, absolute neutrophil count; ATG, antithymocyte globulin; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; TMP-SMX, trimethoprim-sulfamethoxazole; WBC, white blood cell count.